News from dalcor pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Apr 09, 2018, 08:30 ET DalCor Pharmaceuticals Announces Dr. Fouzia Laghrissi-Thode as Chief Executive Officer

DalCor Pharmaceuticals today announced the appointment of Dr. Fouzia Laghrissi-Thode as Chief Executive Officer, effective April 3, 2018. Dr....


Apr 05, 2018, 08:30 ET DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial

DalCor today announced that the company will increase enrollment in its ongoing Phase 3 clinical trial of dalcetrapib from 5000 to 6000 patients. The ...


Nov 15, 2017, 17:13 ET DalCor Pharmaceuticals Appoints Dr. Fouzia Laghrissi-Thode to the Board of Directors

DalCor Pharmaceuticals today announced the appointment of Dr. Fouzia Laghrissi-Thode to its Board of Directors. Dr. Laghrissi-Thode is Vice-President ...


Aug 28, 2017, 03:00 ET DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial

DalCor Pharmaceuticals today announced it has exceeded its enrollment schedule with 50 percent of patients randomized in its Phase 3 "dal-GenE"...


Mar 31, 2017, 12:45 ET DalCor Pharmaceuticals to Present at Needham & Co. Healthcare Conference

DalCor Pharmaceuticals today announced that senior management will participate at the 16th Needham & Co. Healthcare Conference taking place April...


Mar 07, 2017, 07:00 ET DalCor's Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule

DalCor Pharmaceuticals today announced it is ahead of the enrollment schedule with the randomization of over 1,000 patients of the expected 5,000...


Nov 10, 2016, 07:15 ET DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans

DalCor Pharmaceuticals today announced the key investigator in dalcetrapib trials, Jean-Claude Tardif, C.M., M.D., FRCPC, FACC, FAHA, FESC, will...


Aug 23, 2016, 08:00 ET DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial

DalCor Pharmaceuticals today announced the opening of multiple international clinical trial sites in New Zealand and Europe for its Phase 3 dal-GenE...


Jul 19, 2016, 08:08 ET Dalcetrapib von DalCor zeigt vom Genotyp abhängige Wirkungen auf Cholersterinabfluss und Entzündungen - das Montreal Heart Institute veröffentlicht entsprechende Daten in Circulation: Cardiovascular Genetics

DalCor Pharmaceuticals und das Montreal Heart Institute gaben heute die Veröffentlichung von Daten in Circulation: Cardiovascular Genetics bekannt,...


Jul 19, 2016, 01:46 ET Dalcetrapib, de DalCor, demuestra los efectos dependientes del genotipo en el eflujo del colesterol e inflamación

- Dalcetrapib, de DalCor, demuestra los efectos dependientes del genotipo en el eflujo del colesterol e inflamación en los datos publicados por The...


Jul 18, 2016, 09:41 ET Selon les données publiées par l'Institut de Cardiologie de Montréal dans la revue Circulation: Cardiovascular Genetics, le dalcétrapib de DalCor a démontré des effets liés au génotype du patient relativement à l'efflux de cholestérol et à l'inflammation

Les effets obtenus sur la protéine C réactive et l'efflux de cholestérol appuient les bienfaits du dalcétrapib relativement à la diminution des...


Jul 18, 2016, 09:18 ET DalCor's Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics

DalCor Pharmaceuticals and The Montreal Heart Institute today announced the publication in Circulation: Cardiovascular Genetics of data demonstrating ...


Apr 26, 2016, 08:30 ET DalCor randomisiert den ersten Patienten in der DalGenE kardiovaskulären Phase-III-Ergebnisstudie

DalCor Pharmaceuticals gab heute bekannt, dass man den ersten Patienten in der klinischen „dal-GenE" Phase-III-Studie randomisiert hat, einer...


Apr 26, 2016, 08:30 ET DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial

DalCor Pharmaceuticals today announced it has randomzied the first patient in the Phase 3 "dal-GenE" clinical trial, a cardiovascular outcomes study...


Apr 26, 2016, 08:30 ET DalCor randomise un premier patient dans le cadre du lancement de « dal-GenE », essai clinique cardiovasculaire de phase 3

DalCor Pharmaceutiques a annoncé aujourd'hui que la société avait randomisé le premier patient de l'essai clinique « dal-GenE » de phase 3, étude des ...


Apr 26, 2016, 04:21 ET DalCor selecciona aleatoriamente al primer paciente para el ensayo cardiovascular de fase 3 DalGenE

DalCor Pharmaceuticals ha anunciado hoy que ha seleccionado aleatoriamente al primer paciente en el ensayo clínico de fase 3 "dal-GenE", un estudio...


Apr 19, 2016, 12:05 ET DalCor Pharmaceuticals Completes $150 Million Financing

DalCor Pharmaceuticals today announced the completion of $150 million in private financing to continue development of dalcetrapib in a genetically...


Apr 19, 2016, 12:05 ET DalCor Pharmaceuticals schließt 150 Millionen USD-Finanzierung ab

DalCor Pharmaceuticals teilte heute den Abschluss einer privaten Finanzierung in Höhe von 150 Millionen USD zur weiteren Entwicklung von Dalcetrapib...


Apr 19, 2016, 12:05 ET DalCor Pharmaceutiques finalise un financement de 150 millions de dollars

DalCor Pharmaceutiques a annoncé aujourd'hui l'achèvement d'un financement privé de 150 millions de dollars visant à poursuivre le développement du...


Apr 19, 2016, 12:05 ET DalCor Pharmaceuticals completa una financiación de 150 millones de dólares

DalCor Pharmaceuticals ha anunciado hoy el cierre de 150 millones de dólares en financiación privada para seguir el desarrollo de dalcetrapib en una...


Jun 08, 2015, 10:05 ET DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery

New company DalCor to sponsor global phase III clinical trial SAN MATEO, CA, June 8, 2015 /PRNewswire/ - DalCor Pharmaceuticals (DalCor) and the...